Clinical Gastroenterology and Hepatology
February 2017 Volume 15, Issue 2, Pages 289–291
Ushering in an Era Where No Group Who Wants to Be Treated Should Be Excluded
Suthat Liangpunsakul, Paul Y. Kwo
DOI: http://dx.doi.org/10.1016/j.cgh.2016.09.014
Ushering in an Era Where No Group Who Wants to Be Treated Should Be Excluded
Suthat Liangpunsakul, Paul Y. Kwo
DOI: http://dx.doi.org/10.1016/j.cgh.2016.09.014
Download - Full Text Article - PDF
The landscape on the treatment of hepatitis C virus (HCV) has shifted from interferon (IFN)-based therapy to the era of all oral direct acting antiviral (DAA) therapy in December 2013 with the approval of sofosbuvir and ribavirin for HCV genotypes 2 and 3....
The landscape on the treatment of hepatitis C virus (HCV) has shifted from interferon (IFN)-based therapy to the era of all oral direct acting antiviral (DAA) therapy in December 2013 with the approval of sofosbuvir and ribavirin for HCV genotypes 2 and 3....
No comments:
Post a Comment